European Commission Approves Halaven® (Eribulin) for Treatment of Advanced Liposarcoma in Europe (y 2)

Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.

About Eisai Co., Ltd. 

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit http://www.eisai.com.

References 

1. Schöffski P et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2016 

2. Kawano S, et al. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Anticancer Research 2016; 36; 1553-1562 

3. Kevin L Bennewith and Shoukat Dedhar. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 2011;11:504 

4. National Cancer Institute - http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/d...  

5. ESMO Guidance. Available at: http://annonc.oxfordjournals.org/content... Accessed: May 2016 

6. Macmillan. What are soft tissue sarcomas? Available at:  http://www.macmillan.org.uk/Cancerinform... . Accessed: May 2016

7. SPC Halaven (updated November 2015). Available at: http://www.medicines.org.uk/emc/medicine... Accessed: May 2016

8. R Pollock. Soft Tissue Sarcomas, A Volume in the American Cancer Society Atlas of Clinical Oncology Series. 2012 

9. Fletcher, et al. World Health Organization Classification of Tumours of Soft Tissue and Bone (4th Edition). Lyon: IARC Press, 2013 

CONTACT: Media Enquiries: Eisai, Cressida Robson / Ben Speller, +44(0)7908314 155/+44(0) 7908 409416, Cressida_Robson@eisai.net,Ben_Speller@eisai.net, Tonic Life Communications, Alex Davies / CallumHaire, +44 (0)7716 324 722 / +44 (0)7867 429 637, Alex.Davies@toniclc.com,Callum.Haire@toniclc.com